Cellectis S.A. Gains 173.86%
Wed, Nov 01, 2023 at 07:39 PM
Cellectis S.A. (CLLS:NASDAQ) rocketted at $2.64, representing a gain of 173.9%. On Wed, Nov 01, 2023, CLLS:NASDAQ hit a New 2-Week High of $2.64. The stock appeared on our News Catalysts scanner on Wed, Nov 01, 2023 at 04:41 PM in the 'EARNINGS' category. From Wed, Oct 18, 2023, the stock recorded 20.00% Up Days and 9.09% Green Days
About Cellectis S.A. (CLLS:NASDAQ)
Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants.
Top 10 Gainers:
- Cellectis S.A. (CLLS:NASDAQ), 173.86%
- Patriot Transportation Holding, Inc. (PATI:NASDAQ), 103.13%
- Aldeyra Therapeutics, Inc. (ALDX:NASDAQ), 48.54%
- Sientra, Inc. (SIEN:NASDAQ), 32.95%
- Impel NeuroPharma Inc. (IMPL:NASDAQ), 31.45%
- PMV Pharmaceuticals Inc. (PMVP:NASDAQ), 31.13%
- TG Therapeutics, Inc. (TGTX:NASDAQ), 30.92%
- Local Bounti Corporation (LOCL:NYSE), 30.12%
- Precision BioSciences, Inc. (DTIL:NASDAQ), 29.63%
- Silence Therapeutics Plc (SLN:NASDAQ), 29.25%